Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin's lymphoma

Abstract

Anthracyclines have a central role in the management of non-Hodgkin's lymphoma (NHL). The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment regimen has been the standard of care for more than 20 years. Further improvements have been made to the efficacy of this chemotherapy by reducing the dosing interval and adding rituximab to the regimen. A major limitation to the use of anthracyclines is the development of cardiotoxicity as a late adverse event. Strategies to reduce cardiac events include changes to the dosing schedule for doxorubicin, use of the chelating agent dexrazoxane and the use of liposome-encapsulated doxorubicin. This latter strategy has demonstrated good efficacy and reduced cardiotoxicity in patients with NHL, including those at risk of developing cardiac effects.

Introduction

Since their introduction in the 1960s, the anthracyclines have gained a central role in the treatment of non-Hodgkin's lymphoma (NHL). In particular, the use of doxorubicin in the standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen means that a large proportion of patients with aggressive lymphomas receive anthracycline therapy. In this paper, a brief history of the development of anthracyclines, their use in NHL, and the management of anthracycline-related cardiotoxicity are presented.

Development of anthracyclines

The potential of anthracyclines was first recognized in 1960, when Federico Arcamone and co-workers filed a patent application for the “fermentative production and recovery of an antibiotic obtained from Streptomyces krestomyceticus”. In 1963, a novel cytotoxic compound derived from S. peuceticus was isolated simultaneously by researchers in Italy and France. The Italian group gave the compound the name daunomycin, the French group named it rubidomycine. Elements from both names were then combined to give the compound the name daunorubicin. A hydroxylated derivative of daunorubicin was subsequently isolated by the Italian group and called adriamycin. It was later renamed doxorubicin to conform to the established naming convention. In preclinical studies, this new antitumor antibiotic was shown to have greater activity against solid murine tumors and a higher therapeutic index than daunorubicin.^1,2 Early clinical evaluation of doxorubicin demonstrated its efficacy in both adults and children with acute and chronic leukemias.²

The first key demonstration of the efficacy of CHOP in lymphoma was published in 1984. Armitage and co-workers reported the results of a clinical trial in 75 patients treated with CHOP for diffuse histiocytic lymphoma; 51% achieved complete remission and 23 of the complete responders were alive and in complete remission at a median of 38 months after stopping treatment.³ Ten years later, the Southwest Oncology Group and the Eastern Cooperative Oncology Group published the results of a prospective Phase III trial comparing chemotherapy regimens commonly used at that time to treat advanced NHL.⁴ CHOP was therefore compared with MACOP-B (methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin), ProMACE-CytaBOM (prednisone, doxorubicin, cyclophosphamide, etoposide, followed by cytarabine, bleomycin, vincristine, methotrexate with leucovorin rescue), and m-BACOD (methotrexate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone) in 1138 patients (899 eligible for efficacy analysis). There were no significant differences in the efficacy of these regimens, but CHOP was associated with improved safety and tolerability compared with the other regimens (Figure 1). The authors therefore concluded that CHOP remains the best available treatment for patients with advanced-stage intermediate-grade or high-grade NHL.⁴ The efficacy of CHOP in the standard 21-day treatment cycle could be further improved by the use of a 14-day treatment cycle with granulocyte-colony stimulating factor (G-CSF) support in both young and elderly patients.^5,6 Subsequently, it was found that the addition of rituximab to the CHOP regimen further increased its efficacy,^7–10 and that six cycles of R-CHOP plus two additional cycles of rituximab were as effective as eight cycles of R-CHOP.¹¹

Figure 1.

Overall survival of patients with non-Hodgkin's lymphoma receiving three different treatment regimens (3-year estimates of survival).⁴ CHOP – cyclophosphamide, doxorubicin, vincristine, prednisone; m-BACOD – methotre-xate with leucovorin rescue, bleomycin, doxorubicin, cyclo-phosphamide, vincristine, and dexamethasone; ProMACECytaBOM – prednisone, doxorubicin, cyclophosphamide, etoposide, followed by cytarabine, bleomycin, vincristine, methotrexate with leucovorin rescue; MACOP-B – methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin. Reprinted with permission from Fisher RI et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328: 1002-6. ^©Massachusetts Medical Society.

History of anthracycline-related cardiotoxicity

Early studies of doxorubicin did not identify cardiotoxicity as an adverse event. Although the Phase I and II studies did demonstrate electrocardiographic changes in more than half of 97 patients who were prospectively studied, these abnormalities were subclinical, no symptoms were mentioned, and additional research did not suggest any cumulative cardiac toxicity of doxorubicin.¹² However, 10 years after these first studies, cardiotoxicity started to be identified as a late side-effect of cumulative doses of anthracyclines. An early analysis of this problem demonstrated a correlation between the cumulative dose of doxorubicin and the probability of developing congestive heart failure (CHF) (Figure 2).¹³ Subsequent studies confirmed that the incidence of CHF increased from 3% at a cumulative doxorubicin dose of 400 mg/m² to 18% at a cumulative dose of 700 mg/m².¹⁴ Moreover, CHF was often irreversible. Risk factors for cardiotoxicity included: previous exposure to anthracyclines, patient age, and a history of cardiovascular disease.¹⁴ Cardiotoxicity is also seen with newer anthracyclines, such as epirubicin.¹⁵ It is the main factor limiting anthracycline use, and can result in discontinuation or non-use of treatment for patients who might otherwise benefit from this therapy.

Figure 2.

Risk of developing congestive heart failure (CHF) in relation to the cumulative dose of doxorubicin.¹³ Reprinted with permission from Von Hoff DD et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710-17.

Managing anthracycline cardiotoxicity

Treatment strategies designed to reduce anthracycline cardiotoxicity have included modification of the dosing regimen, treatment with cardioprotective agents, and the use of liposome-encapsulated forms of doxorubicin.

Dose and schedule modification

As higher cumulative doses of doxorubicin are associated with a greater risk of CHF, then maintaining doses below a maximum cumulative dose may reduce patients' risks.¹⁶ Nevertheless, such maximum doses cannot be used alone as safe limits for drug treatment, as cardiac dysfunction has been seen in patients receiving lower than maximal doses, and some patients are more susceptible to cardiotoxicity than others.^13,16 Changes to the administration of the anthracycline can also alter its toxicity. Thus, long drug infusions instead of a single injection have been shown to be less cardiotoxic.^17,18 However, this approach is more laborious than conventional treatment, particularly when doxorubicin is used in combination with other agents.

Use of dexrazoxane

Several studies have investigated the use of dexrazoxane, an iron-chelating agent that scavenges free radicals, as a means of limiting anthracycline-related cardiotoxicity. Initially, there were concerns that this agent might adversely affect the antitumor activity of doxorubicin.¹⁹ However, a subsequent systematic review of nine randomized trials found that dexrazoxane significantly reduced patients' risk of developing CHF, without affecting the efficacy of doxorubicin, in terms of response rate or survival. The authors therefore concluded that dexrazoxane treatment should be considered in patients at high risk of cardiotoxicity.²⁰

Use of liposome-encapsulated doxorubicin

Two liposome-encapsulated forms of doxorubicin are currently available: pegylated liposomal doxorubicin and non-pegylated liposomal doxorubicin (NPLD). Liposomes are microscopic structures consisting of one or more concentric lipid bilayers, which encapsulate the active substance. These lipid structures cannot escape the vascular space in areas that have tight capillary junctions, such as the heart muscle, but can reach other tissues. Thus, the pharmacokinetics and tissue distribution of the active molecule are modified. In particular, NPLD is preferentially delivered to the liver, spleen, bone marrow, and lymph nodes, compared with relatively little entry to cardiac muscle and the gastrointestinal mucosa.²¹ This treatment may therefore reduce the cardiac toxicity of doxorubicin while maintaining its antitumor efficacy.

In patients with newly diagnosed aggressive NHL, substitution of NPLD into the CHOP regimen, to give COMP, produced a complete response rate of 67.4%.²² Importantly, the use of COMP in patients at risk of cardiotoxicity has also produced promising results. A retrospective analysis of rituximab-COMP (R-COMP) treatment for patients who either had concurrent cardiac diseases or had been pretreated with anthracyclines demonstrated a complete response rate of 76%.²³ Moreover, only one patient included in this analysis developed acute grade III cardiotoxicity. A prospective international study of R-COMP in elderly patients with aggressive lymphoma gave a complete remission rate of 57%, and patients showed no signs of cardiotoxicity. Left ventricular ejection fraction did not change during treatment, and the R-COMP regimen was not associated with any increase in acute cardiac toxicity.²⁴ A meta-analysis of two studies comparing free and liposomal doxorubicin (in patients with breast cancer, not NHL) showed a significantly lower rate of both clinical heart failure, and clinical and subclinical heart failure combined, in patients treated with liposome-encapsulated doxorubicin.¹⁵

Conclusions

Anthracyclines continue to play a central role in the treatment of NHL. Moreover, the introduction of liposome-encapsulated doxorubicin may allow their use to be extended to patients at risk of cardiotoxicity who would benefit from this treatment. A key challenge now in NHL is to maximize treatment outcomes, through new biological approaches such as gene profiling, and through optimal use of therapies across the diverse spectrum of lymphomas. This challenge to clinicians was the theme of an international workshop, Moving forward with new data and approaches: a fresh look at anthracyclines in breast cancer and NHL, which took place in Meldola, Italy, in September 2010. This meeting reviewed recent data on the use of anthracyclines in the treatment of breast cancer and NHL, with the aim of providing guidance on how the management of these diseases can be improved. The presentations on NHL at this meeting are summarized in this supplement.